Of Vanishing Retinal Drusen and Oxysterols

2018 ◽  
Vol 27 (9) ◽  
pp. 1-12
Author(s):  
Stuart Richer ◽  
Sherwin Nassiri ◽  
Avni Dervishi ◽  
Harsh Patel ◽  
Anish Bhandari ◽  
...  
Keyword(s):  
Retinal Drusen

scholarly journals Retinal drusen: harbingers of age, safe havens for trouble

2009 ◽  
Vol 38 (6) ◽  
pp. 648-654 ◽  
Author(s):  
M. A. Williams ◽  
D. Craig ◽  
P. Passmore ◽  
G. Silvestri
Keyword(s):  
Retinal Drusen

scholarly journals Quantum-Assisted Retinal Drusen Detection Algorithm using Entropy-Based Image Processing Techniques

2020 ◽  
Vol 9 (3) ◽  
pp. 2251-2256
Keyword(s):  
Image Processing ◽  
Composite System ◽  
Detection Method ◽  
Research Work ◽  
Detection Algorithm ◽  
Image Processing Techniques ◽  
Sensitivity Specificity ◽  
Processing Techniques ◽  
Retinal Fundus ◽  
Retinal Drusen

Drusen identification is the fundamental operation in the automated diagnosis of eye diseases. Manual and automatic detection of the drusen in the retinal fundus images has been developed recently in the classical manner only. This work provides the quantum-based retinal drusen detection method using entropy-based image processing techniques. This algorithm is the composite system of two channels, classical and quantum channels for the preprocessing and drusen detection respectively. This research work has been evaluated with the databases of DRIVE, STARE, MESSIDOR, E-Optha-Ex and ONH-Hunter. This quantum-based approach will be analyzed with the results of the existing classical methods and proves its efficiency from the calculations of sensitivity, specificity, accuracy and execution time.

Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL)

2021 ◽  
pp. practneurol-2021-003058
Author(s):  
Rhea YY Tan ◽  
Anna M Drazyk ◽  
Kathryn Urankar ◽  
Clare Bailey ◽  
Stefan Gräf ◽  
...  
Keyword(s):  
Autosomal Recessive ◽  
Small Vessel Disease ◽  
Postmortem Brain ◽  
Small Vessel ◽  
Retrospective Diagnosis ◽  
Vessel Disease ◽  
Brain Scan ◽  
Mr Brain ◽  
Retinal Drusen ◽  
Brain Examination

A 44-year-old Caucasian man presented with seizures and cognitive impairment. He had marked retinal drusen, and MR brain scan showed features of cerebral small vessel disease; he was diagnosed with a leukoencephalopathy of uncertain cause. He died at the age of 46 years and postmortem brain examination showed widespread small vessel changes described as a vasculopathy of unknown cause. Seven years postmortem, whole-genome sequencing identified a homozygous nonsense HTRA1 mutation (p.Arg302Ter), giving a retrospective diagnosis of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy.

scholarly journals Calcified nodules in retinal drusen are associated with disease progression in age-related macular degeneration

2018 ◽  
Vol 10 (466) ◽  
pp. eaat4544 ◽  
Author(s):  
Anna C. S. Tan ◽  
Matthew G. Pilgrim ◽  
Sarah Fearn ◽  
Sergio Bertazzo ◽  
Elena Tsolaki ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Age Related Macular Degeneration ◽  
Human Eye ◽  
Age Related ◽  
Increased Risk ◽  
Risk Of Progression ◽  
Retinal Drusen ◽  
Independent Cohort

Drusen are lipid-, mineral-, and protein-containing extracellular deposits that accumulate between the basal lamina of the retinal pigment epithelium (RPE) and Bruch’s membrane (BrM) of the human eye. They are a defining feature of age-related macular degeneration (AMD), a common sight-threatening disease of older adults. The appearance of heterogeneous internal reflectivity within drusen (HIRD) on optical coherence tomography (OCT) images has been suggested to indicate an increased risk of progression to advanced AMD. Here, in a cohort of patients with AMD and drusen, we show that HIRD indicated an increased risk of developing advanced AMD within 1 year. Using multimodal imaging in an independent cohort, we demonstrate that progression to AMD was associated with increasing degeneration of the RPE overlying HIRD. Morphological analysis of clinically imaged cadaveric human eye samples revealed that HIRD was formed by multilobular nodules. Nanoanalytical methods showed that nodules were composed of hydroxyapatite and that they differed from spherules and BrM plaques, other refractile features also found in the retinas of patients with AMD. These findings suggest that hydroxyapatite nodules may be indicators of progression to advanced AMD and that using multimodal clinical imaging to determine the composition of macular calcifications may help to direct therapeutic strategies and outcome measures in AMD.

Retinal Drusen and Colour Vision

1984 ◽  
pp. 355-361 ◽  
Author(s):  
J. L. Vola ◽  
C. Poli ◽  
P. Gastaud ◽  
G. LePrince
Keyword(s):  
Colour Vision ◽  
Retinal Drusen

Aquaporin-1 Expression in Retinal Pigment Epithelial Cells Overlying Retinal Drusen

2016 ◽  
Vol 55 (4) ◽  
pp. 180-184 ◽  
Author(s):  
Thuy Linh Tran ◽  
Toke Bek ◽  
Morten la Cour ◽  
Jan Ulrik Prause ◽  
Steffen Hamann ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Retinal Pigment Epithelial ◽  
Retinal Pigment ◽  
Retinal Pigment Epithelial Cells ◽  
Aquaporin 1 ◽  
Pigment Epithelial ◽  
Retinal Drusen ◽  
Pigment Epithelial Cells

PERIPHERAL RETINAL DRUSEN–LIKE DEPOSITS IN GUCY2C CONGENITAL SECRETORY DIARRHEA SYNDROME

2018 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Dean Cugley ◽  
Nicholas Brislane ◽  
Robyn Guymer ◽  
Susan Carden
Keyword(s):  
Secretory Diarrhea ◽  
Diarrhea Syndrome ◽  
Retinal Drusen

scholarly journals Visual Function and Macular Carotenoid Changes in Eyes with Retinal Drusen—An Open Label Randomized Controlled Trial to Compare a Micronized Lipid-Based Carotenoid Liquid Supplementation and AREDS-2 Formula

Nutrients ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3271
Author(s):  
Pinakin Gunvant Davey ◽  
Thomas Henderson ◽  
Drake W. Lem ◽  
Rebecca Weis ◽  
Stephanie Amonoo-Monney ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Contrast Sensitivity ◽  
Dark Adaptation ◽  
Age Related Macular Degeneration ◽  
Visual Performance ◽  
Control Group ◽  
Open Label ◽  
Treatment Groups ◽  
Age Related ◽  
Retinal Drusen

Purpose: To compare the changes in visual and ocular parameters in individuals with retinal drusen who were treated with two commercially available nutritional supplements. Methods: An open-label, single-center, randomized, parallel-treatment with an observational control group design was utilized. The treatment groups included individuals with fine retinal drusen sub-clinical age-related macular degeneration (AMD), while the control group consisted of ocular normal individuals. The treatment groups were randomly assigned to the micronized lipid-based carotenoid supplement, Lumega-Z (LM), or the PreserVision Age-Related Eye Disease Study 2 (AREDS-2) soft gel (PV). Visual performance was evaluated using the techniques of visual acuity, dark adaptation recovery and contrast sensitivity, at baseline, three months, and six months. Additionally, the macular pigment optical density (MPOD) was measured. The control group was not assigned any carotenoid supplement. The right eye and left eye results were analyzed separately. Results: Seventy-nine participants were recruited for this study, of which 68 qualified and 56 participants had useable reliable data. Of the individuals who completed this study, 25 participants belonged to the LM group, 16 belonged to the PV group, and 15 to the control group. The LM group demonstrated statistically significant improvements in contrast sensitivity function (CSF) in both eyes at six months (p < 0.001). The LM group displayed a positive linear trend with treatment time in CSF (p < 0.001), with benefits visible after just three months of supplementation. Although there was a trend showing improvement in CSF in the PV group, the change was not significant after a Bonferroni-corrected p-value of p < 0.00625. Visual acuity, dark adaptation recovery and MPOD did not significantly improve in either treatment groups. Conclusion: The LM group demonstrated greater and faster benefits in visual performance as measured by CSF when compared to the PV group. This trial has been registered at clinicaltrials.gov (NCT03946085).

Sign in / Sign up

Export Citation Format

Share Document